Dupilumab proven effective for atopic dermatitis in real-life study
The efficacy of dupilumab for the treatment of atopic dermatitis (AD) seen in clinical trials has been similarly observed in this real-life study. However, treatment with dupilumab is associated with a higher incidence of conjunctivitis and eosinophilia.
“Dupilumab is the first biologic available to treat AD,” the authors said. “Its effectiveness and safety were demonstrated in clinical trials.”
A total of 241 patients were included, with a median follow-up of 3.8 months. Twenty-seven of 163 (16.6 percent) patients achieved a ≥75-percent improvement in the Scoring Atopic Dermatitis (SCORAD), and 40 of 82 (48.8 percent) patients attained a ≥75-percent improvement in the Eczema Area and Severity Index (EASI). At 3 months, median SCORAD and EASI scores were significantly lower than those at baseline (SCORAD, 25±21 vs 56±27.4; p<10−9; EASI, 4.1±6.8 vs 17.9±15.4; p<10−9)
Eighty-four of 241 (38.2 percent) patients reported conjunctivitis. Moreover, eosinophilia (>500 cells/mm3) cases were higher during follow-up than at baseline (57 percent vs 33.7 percent; n=172; p<10−6). Treatment cessation occurred in 42 patients, among whom 27 discontinued due to adverse events (AEs).
To assess the safety and efficacy of dupilumab in adults with AD, the authors enrolled patients treated between March 2017 and April 2018 in a real-life French multicentre retrospective cohort study. The authors collected efficacy outcomes, including SCORAD and EASI scores, at baseline and at 3 months when available. They also recorded the incidence of AEs at follow-up.
The study has certain limitations, including the absence of a control group and of some missing data, according to the authors.